Literature DB >> 23356280

The activation of the CGRP receptor.

James Barwell1, Mark Wheatley, Alex C Conner, Bruck Taddese, Shabana Vohra, Christopher A Reynolds, David R Poyner.   

Abstract

The CGRP (calcitonin gene-related peptide) receptor is a family B GPCR (G-protein-coupled receptor). It consists of a GPCR, CLR (calcitonin receptor-like receptor) and an accessory protein, RAMP1 (receptor activity modifying protein 1). RAMP1 is needed for CGRP binding and also cell-surface expression of CLR. CLR is an example of a family B GPCR. Unlike family A GPCRs, little is known about how these receptors are activated by their endogenous ligands. This review considers what is known about the activation of family B GPCRs and then considers how this might be applied to CLR, particularly in light of new knowledge of the crystal structures of family A GPCRs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23356280     DOI: 10.1042/BST20120251

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  4 in total

1.  Sex Differences in CGRP Regulation and Function in the Amygdala in a Rat Model of Neuropathic Pain.

Authors:  Peyton Presto; Volker Neugebauer
Journal:  Front Mol Neurosci       Date:  2022-06-03       Impact factor: 6.261

Review 2.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

3.  Calcitonin Gene-Related Peptide-Induced Calcium Alginate Gel Combined with Adipose-Derived Stem Cells Differentiating to Osteoblasts.

Authors:  Chang-Zhi Huang; Xiao-Ning Yang; Da-Cheng Liu; Yi-Gong Sun; Xing-Ming Dai
Journal:  Cell Biochem Biophys       Date:  2015-12       Impact factor: 2.194

Review 4.  Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.

Authors:  Fred Cohen; Hsiangkuo Yuan
Journal:  Ther Clin Risk Manag       Date:  2022-04-22       Impact factor: 2.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.